Wright Medical Group N.V

Wright Medical — Merger or Acquisition (November 2014)

26 slides from Wright Medical's merger presentation, Nov 20, 2014

  1. Slide 1: Investor Presentation 3Q 2014

    Investor Presentation 3 Q 2 0 1 4 Filed by Tornier N.V. (SEC File No.: 001-35065) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Wright Medical Group, Inc. SEC File No.: 001-35823

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations of future ev

  3. Slide 3: Non-GAAP Financial Measures

    NON-GAAP FINANCIAL MEASURES Non-GAAP Financial Measures Tornier uses certain non-GAAP financial measures in this presentation, such as adjusted EBITDA, adjusted gross margin and constant currency. Tornier uses non-GAAP financial measures as supplemental measures of performance and believes these mea

  4. Slide 4: Tornier Is… Global Medical Device Company

    TORNIER IS… Global Medical Device Company, focusing on providing superior solutions to surgeons treating orthopaedic extremities injuries & disorders

  5. Slide 5: Tornier Is Well-Positioned for Long-Term Growth and Margin Expansion

    TORNIER IS WELL-POSITIONED FOR LONG-TERM GROWTH AND MARGIN EXPANSION HIGH GROWTH MARKET Extremities COMPREHENSIVE PRODUCT PORTFOLIO ENHANCED GROWTH AND PROFITABILITY UPPER EXTREMITIES LOWER EXTREMITIES Robust Drivers Enable Sustained Growth $6.5B 8-9% CAGR (’14 – ’18) Based upon management estimates

  6. Slide 6: Tornier

    TORNIER

  7. Slide 7: Tornier Is Focused on Robust, High-Growth Markets

    TORNIER IS FOCUSED ON ROBUST, HIGH-GROWTH MARKETS Tornier’s goal is to leverage its dedicated sales force and strong product portfolio to drive above market growth in upper and lower extremities

  8. Slide 8: Extremity Market Drivers Provide Opportunity for Sustained Growth

    EXTREMITY MARKET DRIVERS PROVIDE OPPORTUNITY FOR SUSTAINED GROWTH • Extremities specific design • Unmet need for early intervention • Growing need for revision • Facilitating minimally invasive procedures TECHNOLOGY • Aging population • Growing awareness (globally) • “Quality of life” expectations P

  9. Slide 9: Tornier Is Well-Positioned for Long-Term Growth: Comprehensive Product Portfolio

    TORNIER IS WELL-POSITIONED FOR LONG-TERM GROWTH COMPREHENSIVE PRODUCT PORTFOLIO UPPER EXTREMITIES LOWER EXTREMITIES Based upon management estimates Leader in Innovation, Science & Education Robust Drivers Enable Sustained Growth $6.5B 8-9% CAGR (’14 – ’18) FOCUSED ON EXECUTION Proposed Merger with W

  10. Slide 10: Comprehensive Portfolio Provides Full-Line Support to the Extremity Surgeon

    COMPREHENSIVE PORTFOLIO PROVIDES FULL-LINE SUPPORT TO THE EXTREMITY SURGEON JOINT REPLACEMENTS BONE REPAIR BIOLOGICS SOFT TISSUE REPAIR Number of Extremities Products: UPPER Shoulder, Elbow, Hand & Wrist LOWER Foot & Ankle PROCEDURES

  11. Slide 11: Portfolio Strategy Leverages Strengths to Take Share While Expanding Extremity Markets

    PORTFOLIO STRATEGY LEVERAGES STRENGTHS TO TAKE SHARE WHILE EXPANDING EXTREMITY MARKETS JOINT REPLACEMENTS BONE REPAIR BIOLOGICS SOFT TISSUE REPAIR 1. Take Share through introduction of best-in-class extremity specific solutions 2. Expand arthroplasty markets with early intervention products 3. Creat

  12. Slide 12: Our Foundation for Sustained Above Market Growth

    OUR FOUNDATION FOR SUSTAINED ABOVE MARKET GROWTH Near-Term Long-Term Strategic Investments to Leverage Dedicated Sales Channels: 1. Creating Competitively Superior Sales Rep 2. Providing Best-in-Class UE / LE Products 3. Market Expansion through Indication

  13. Slide 13: Sustaining Above Market Growth Through Focused Execution

    SUSTAINING ABOVE MARKET GROWTH THROUGH FOCUSED EXECUTION Best-in-Class Products Driving Current Growth Market Expansion Indication Driven Product Development Ascend Flex Platform • TSA / RSA Convertible Stem • PerForm Glenoid • Reversed Threaded Post Baseplate Salto Talaris 2.1 Cannulink, Cannulink+

  14. Slide 14: Tornier Is the Go-To Extremities Company with Industry Leading Science & Education

    TORNIER IS THE “GO-TO” EXTREMITIES COMPANY WITH INDUSTRY LEADING SCIENCE & EDUCATION PROGRAMS RESPECTED FOR SCIENTIFIC RIGOR SUPPORTING ACTIVE FUNDAMENTAL RESEARCH • Pyrolytic carbon • Advanced kinematic & biomechanical testing capability • Computer Aided Surgery & 3D Pre-operative planning COMMITTE

  15. Slide 15: Tornier Is Well-Positioned for Long-Term Growth

    TORNIER IS WELL-POSITIONED FOR LONG-TERM GROWTH ENHANCED GROWTH AND PROFITABILITY HIGH GROWTH MARKET COMPREHENSIVE PRODUCT PORTFOLIO Extremities Robust Drivers Enable Sustained Growth $6.5B 7-9% CAGR (’14 – ’18) Proposed Merger with Wright Medical Will Create Premier Extremities and Biologics Compan

  16. Slide 16: Tornier Conducts International Sales Operations in Distinct Countries

    TORNIER CONDUCTS INTERNATIONAL SALES OPERATIONS IN DISTINCT COUNTRIES ON CONTINENTS Primarily direct sales Primarily distributor Mixed Model Country Office International revenue $128.9 MM (41% of Total)* *2013 revenue results

  17. Slide 17: Three Strategic Initiatives to Strengthen Our International Business

    THREE STRATEGIC INITIATIVES TO STRENGTHEN OUR INTERNATIONAL BUSINESS STRENGTHEN BRAND IN EMERGING MARKETS ACCELERATE REVENUE GROWTH DRIVE ADOPTION IN DEVELOPED GEOGRAPHIES 1 2 3 • Select investments to accelerate presence in Brazil & China • Evaluate targeted expansion plans in other emerging market

  18. Slide 18: Continue to Invest to Build a Superior U.S. Sales Force

    CONTINUE TO INVEST TO BUILD A SUPERIOR U.S. SALES FORCE Competitively Superior DESIRED STATE Proficient & Productive 2014/2015 – PHASE II Reps aligned to UE / LE Continue to fill territories • Exclusive UE / LE channels • Expanded portfolio • Narrow rep territories • Reps provide “value-add” Agreeme

  19. Slide 19: Today (Q3 2014) Completed Significant Transitions Within U.S. Sales Channel

    TODAY (Q3 2014) COMPLETED SIGNIFICANT TRANSITIONS WITHIN U.S. SALES CHANNEL EXITING 2012 US Sales Network • U.S. revenue $182.1 MM (59% of Total)* • > 85% US revenues represented by dedicated UE or LE sales reps • 165 U.S. direct sales reps (365 total U.S. reps) Distributor Direct US Sales Network •

  20. Slide 20: Work Remains to Build a Best-in-Class U.S. Sales Force

    WORK REMAINS TO BUILD A “BEST-IN-CLASS” U.S. SALES FORCE Agreements & Alignment Distributor Negotiation US Sales Channel Transition Sales Mgmt. & Training Org. Timing Desired State Rep Training & Education Performance & Productivity High Uncertainty Strong & Reliable Performance Territory Staffing

  21. Slide 21: Plans to Deliver Consistent Above-Market Growth and Strong Financial Performance

    Above Market CAGR Upper Extrm. 20% of Rev PLANS TO DELIVER CONSISTENT ABOVE-MARKET GROWTH AND STRONG FINANCIAL PERFORMANCE EBITDA Leverage Lower Extrm. Projected Extremities Revenues • Driving above-market growth in upper and lower extremity segments • Revenue geographically balanced • 3Q results in

  22. Slide 22: 2014 Financial Guidance and Key Metrics

    2014 FINANCIAL GUIDANCE AND KEY METRICS Financial Guidance (1) Revenue (2) : 4Q: $85 to $89 million, 1.9% to 6.7% growth FY: $334.9 to $338.9 million, 7.7% to 9.0% growth Extremities revenue (2) : 4Q: $70.5 to $73.5 million, 3.5% to 7.9% growth FY: $278.8 to $281.8 million, 8.1% to 9.2% growth Adjus

  23. Slide 23: Wright and Tornier Agree to Merge

    WRIGHT AND TORNIER AGREE TO MERGE Wright and Tornier Agree to Merge Creating Premier High-Growth Extremities-Biologics Company Combination Will Offer Comprehensive Upper and Lower Extremity Product Portfolio and Broad Global Reach Further Accelerates Growth Opportunities in Three of the Fastest Grow

  24. Slide 24: Transaction Overview

    TRANSACTION OVERVIEW • All stock transaction resulting in a combined equity value of approx. $3.3B – Combined company ownership: 52% Wright / 48% Tornier existing shareholders • For Tornier shareholders, exchange ratio implies a per share value for Tornier that represents a 28% premium to Tornier’s

  25. Slide 25: Tornier Is Well-Positioned for Long-Term Growth

    TORNIER IS WELL-POSITIONED FOR LONG-TERM GROWTH HIGH GROWTH MARKET COMPREHENSIVE PRODUCT PORTFOLIO ENHANCED GROWTH AND PROFITABILITY Based upon management estimates Robust Drivers Enable Sustained Growth Leader in Innovation, Science & Education Proposed Merger with Wright Medical Will Create Premie

  26. Slide 26: Thank You

    THANK YOU

Wright Medical Group — Merger or Acquisition (November 2014) on 6ix